Elisabetta Petracci

Meldola, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 65 publications

MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.

MiracleNet: A Biologically Interpretable Machine Learning Model for Resected Non-small-cell Lung Cancer.

Journal: Computational and structural biotechnology journal

Published: March 21, 2026

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Journal: Hematological oncology

Published: November 10, 2025

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study.

Journal: British journal of haematology

Published: July 29, 2025

Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients.

Genomic and Transcriptomic Profiles in Smokers and Never-Smokers Lung Squamous Cell Carcinoma Patients.

Journal: Lung Cancer (Auckland, N.Z.)

Published: January 23, 2025

Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.

Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA.

Journal: Scientific reports

Published: December 05, 2024

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.

Journal: Cancer

Published: November 22, 2024

Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients.

Comprehensive genetic and epigenetic characterization of Lynch-like syndrome patients.

Journal: International journal of cancer

Published: October 28, 2024

INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.

INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia.

Journal: Cancer

Published: October 22, 2024

HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer.

HDAC6 as a Prognostic Factor and Druggable Target in HER2-Positive Breast Cancer.

Journal: Cancers

Published: October 14, 2024

Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial.

Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial.

Journal: ESMO open

Published: September 11, 2024

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.

Journal: American journal of hematology

Published: September 05, 2024

Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Assessment of circulating tumor DNA in patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Journal: Scientific reports

Published: August 29, 2024

Showing 1-12 of 65

Last Updated: 09/26/2026